Previous Close | 0.6500 |
Open | 0.6500 |
Bid | 0.6500 x 0 |
Ask | 0.6700 x 0 |
Day's Range | 0.6500 - 0.6700 |
52 Week Range | 0.4000 - 0.7000 |
Volume | |
Avg. Volume | 48,504 |
Market Cap | 52.05M |
Beta (5Y Monthly) | 1.40 |
PE Ratio (TTM) | 11.17 |
EPS (TTM) | 0.0600 |
Earnings Date | Aug 24, 2022 - Aug 29, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Recognized commercial leader with over 20 years of experience across diverse healthcare industries Appointment marks strategic step in driving Company towards next phase of growth EDMONTON, Alberta, July 12, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the appointment of Sigrun Watson as
EDMONTON, Alberta, June 07, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors were elected to serve for a one-year term at its Annual General and Special Meeting of Shareholders held on June 1, 2022 as per the following results: NomineeVotes forVotes withheld% of v
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...